POMPANO BEACH, Fla., Sept. 30, 2024 (GLOBE NEWSWIRE) — BioStem Applied sciences, Inc. BSEM (“BioStem” or the “Firm”), a number one MedTech firm centered on the event, manufacture and commercialization of placental-derived biologics, publicizes the submitting of a Type 10 registration assertion (the “Registration Assertion”) with the U.S. Securities and Alternate Fee (the “SEC”) on September 27, 2024 to register its shares of widespread inventory pursuant to the Securities Alternate Act of 1934, as amended, and reaffirms its strategic choice to pursue an inventory on the Nasdaq Inventory Market (“Nasdaq”).
Type 10 Submitting:
Submitting the Registration Assertion marks a pivotal step within the Firm’s technique to uplist to Nasdaq. This submitting displays the Firm’s ongoing dedication to transparency and robust company governance, offering buyers with detailed insights into its operations and monetary efficiency. As soon as the Registration Assertion turns into efficient 60 days from the submitting date, BioStem shall be a completely reporting firm with the SEC, topic to quarterly, annual and different reporting necessities. BioStem expects that attaining full reporting standing won’t solely improve the Firm’s credibility out there however will even place The Firm for higher visibility and entry to capital, in the end driving shareholder worth because it pursues its development goals.
Compliance with Nasdaq Itemizing Necessities:
BioStem’s plan to uplist to Nasdaq is contingent upon approval and assembly the mandatory itemizing and regulatory necessities. The corporate’s widespread inventory will proceed to commerce on the OTC market underneath the ticker image “BSEM” till BioStem is ready to uplist to Nasdaq. BioStem is dedicated to maximizing shareholder worth by way of itemizing on a serious change, and Nasdaq offers a strong and environment friendly buying and selling platform that gives elevated visibility and liquidity alternatives for institutional and retail buyers worldwide. Along with submitting the Registration Assertion, BioStem lately introduced that it has strengthened its compliance and reporting framework as a part of the uplisting course of by finishing two years of audited monetary statements.
Jason Matuszewski, CEO of BioStem Applied sciences, commented: “Our choice to pursue a serious change itemizing marks a pivotal improvement throughout a interval of continued income development. Uplisting to Nasdaq aligns with our strategic initiatives to reinforce market visibility, monetary transparency and entry to capital as we proceed to develop by way of capital markets actions. BioStem is dedicated to driving income development and market growth for our merchandise, and we are going to present updates on our medical trials and itemizing goals as information turns into out there. We stay up for working intently with Nasdaq and updating our stakeholders all through this course of as we pursue our itemizing goals.”
About BioStem Applied sciences, Inc. BSEM: BioStem Applied sciences, Inc. is a number one innovator centered on harnessing the pure properties of perinatal tissue within the improvement, manufacture and commercialization of allografts for regenerative therapies. The Firm is targeted on manufacturing merchandise that change lives, leveraging its proprietary BioREtain® processing technique. BioREtain® has been developed by making use of the most recent analysis in regenerative medication, centered on sustaining development elements and preserving tissue construction. The Firm’s high quality administration system and normal working procedures have been reviewed and accredited by the American Affiliation of Tissue Banks (“AATB”). These techniques and procedures are established per present Good Tissue Practices (“cGTP”) and present Good Manufacturing Processes (“cGMP”). Our portfolio of high quality manufacturers consists of AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Every BioStem placental allograft is processed on the Firm’s U.S. Federal and Drug Administration (FDA) registered and AATB-accredited web site in Pompano Seaside, Florida. For extra info go to biostemtechnologies.com and observe us on Twitter and Linkedin.
Ahead-Trying Statements: Apart from statements of historic truth, this press launch additionally comprises forward-looking statements. These forward-looking statements relate to expectations or forecasts of future occasions. Ahead-looking statements could also be recognized utilizing phrases reminiscent of “forecast,” “intend,” “search,” “goal,” “anticipate,” “imagine,” “count on,” “estimate”, “plan,” “outlook,” and “mission” and different comparable expressions that predict or point out future occasions or traits or that aren’t statements of historic issues. Ahead-looking statements on this press launch embrace statements concerning the Firm’s: (i) capacity to satisfy the itemizing necessities and efficiently uplist to Nasdaq; (ii) capacity to spice up liquidity alternatives and advance its industrial and medical initiatives; (iii) ongoing dedication to transparency and robust company governance; (iv) capacity to advertise credibility, enhance visibility and entry to capital whereas maximizing shareholder worth; (v) development goals, together with capacity to develop by way of capital market actions, and the affect that will have on the Firm’s enterprise and monetary situation and (vi) capacity to maintain income development and drive market growth for the Firm’s merchandise. Ahead-looking statements with respect to the operations of the Firm, methods, prospects and different facets of the enterprise of the Firm are based mostly on present expectations which can be topic to identified and unknown dangers and uncertainties, which might trigger precise outcomes or outcomes to vary materially from expectations expressed or implied by such forward-looking statements. These elements embrace, however are usually not restricted to: the chance that the Firm could also be unable to listing BSEM’s inventory on Nasdaq or keep compliance with Nasdaq’s continued itemizing requirements; the affect of any modifications to the reimbursement ranges for the Firm’s merchandise; the competitors that the Firm faces, which might adversely have an effect on its enterprise, outcomes of operations and monetary situation; fast technological change might trigger the Firm’s merchandise to develop into out of date and if the Firm doesn’t improve its product choices by way of its analysis and improvement efforts, it could be unable to successfully compete; the Firm’s capacity to persuade physicians that its merchandise are secure and efficient alternate options to present therapies and that its merchandise must be used of their procedures; the chance that the Firm could also be unable to boost funds to develop its enterprise; modifications in relevant legal guidelines or rules; the likelihood that the Firm could also be adversely affected by different financial, enterprise, and/or aggressive elements; the Firm’s capacity to take care of manufacturing of its merchandise in enough portions to satisfy demand and the truth that the Firm derives a majority of its income from one distributor. You’re cautioned to not place undue reliance upon any forward-looking statements, which communicate solely as of the date made. Though it could voluntarily accomplish that every so often, the Firm undertakes no dedication to replace or revise the forward-looking statements, whether or not because of new info, future occasions or in any other case, besides as required by relevant securities legal guidelines.
BioStem Applied sciences, Inc.
Cellphone: 954-380-8342
Web site: http://www.biostemtechnologies.com
E-Mail: [email protected]
Twitter: @BSEM_Tech
Fb: BioStemTechnologies
PCG Advisory
Jeff Ramson
[email protected]
646-863-6893
Market Information and Knowledge dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
